Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01361568 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate Analgesic Effect of IV Administration of Kappa Agonist CR845 For Hysterectomy Surgery
A Phase 2 study, sponsored by Cara Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 203
- Enrollment target
NCT01361568 is a Phase 2 study that has completed, run by Cara Therapeutics. The registered enrollment target is 203 participants.
The verdict
NCT01361568, a Phase 2 study, has completed, sponsored by Cara Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 203 participants
- Enrollment target
Study Summary
The primary purpose of this study is to determine if CR845 is effective in treating the pain associated with a laparoscopic hysterectomy.
Interventions
- DRUG Placebo
- DRUG CR845
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 203 participants |
| Start Date | 2011-07 |
| Est. Completion | 2012-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01361568
The ClinicalTrials.gov registry entry for NCT01361568 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 203 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cara Therapeutics, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01361568 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01361568 about?
NCT01361568 is a clinical study titled "Study to Evaluate Analgesic Effect of IV Administration of Kappa Agonist CR845 For Hysterectomy Surgery". The primary purpose of this study is to determine if CR845 is effective in treating the pain associated with a laparoscopic hysterectomy.
What is the current status of trial NCT01361568?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 203 participants. The study started on 2011-07. Estimated completion is 2012-04.
What interventions are being tested in trial NCT01361568?
The interventions under investigation include: Placebo (DRUG), CR845 (DRUG).
Who is sponsoring clinical trial NCT01361568?
This trial is sponsored by Cara Therapeutics, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.